LENSAR (LNSR) vs Nyxoah SA (NYXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LENSAR (LNSR) has outperformed Nyxoah SA (NYXH) over the past year, losing 46.9% versus a loss of 78.7%. Over five years, LNSR leads with a -15.3% price change compared with -94.7% for NYXH. Nyxoah SA is the larger company by market cap ($138.5 million vs $78.3 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNSR | NYXH |
|---|---|---|
| Share price | $6.37 | $1.36 |
| Market cap | $78.26M | $138.50M |
| 1-day change | -1.24% | +0.74% |
| YTD return | -45.23% | -70.43% |
| 1-year return | -46.87% | -78.72% |
| 5-year return | -15.29% | -94.67% |
| P/E ratio (TTM) | 35.39 | — |
| EPS (TTM) | $0.18 | $-2.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.94 | $6.60 |
| 52-week low | $4.95 | $1.26 |
| Distance from 52-week high | -50.77% | -79.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +77.86% | +208.82% |
| Average volume | 102.05K | 272.93K |
| Shares outstanding | 12.29M | 101.84M |
| Employees | 150 | 153 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LNSR has outperformed NYXH by 31.8 percentage points over the past year.
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
About Nyxoah SA
NYXH stock →Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
Health Care · Medical/Dental Instruments · 153 employees
LNSR vs NYXH FAQ
Which is bigger, LENSAR or Nyxoah SA?
Nyxoah SA (NYXH) is larger, with a market capitalization of $138.50M compared with $78.26M for LENSAR (LNSR).
Which stock has performed better over the past year, LNSR or NYXH?
LNSR returned -46.87% over the past 12 months, compared with -78.72% for NYXH (price return, excluding dividends). Past performance does not predict future results.
Are LENSAR and Nyxoah SA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.